Olink Bioscience Appoints Patrik Dahlén as Chairman of the Board

30-Sep-2009 - Sweden

Olink Bioscience has announced the appointment of Dr. Patrik Dahlén as Chairman of the Board. As the former CEO of global cancer diagnostics company Dako and with experience from several smaller fast developing biotech companies, Dr. Dahlén will bring invaluable industry insight and a fresh perspective to Olink Bioscience continued expansion. Professor Ulf Landegren, co-founder and the company´s former Chairman of the Board will continue to serve on the BoD and he will continue to bring the company valuable contacts with the scientific community in Uppsala and internationally

Dr. Dahlén has occupied high level positions within the diagnostics and life sciences sector for over 15 years. Prior to his four year tenure at Dako from 2005 to January 2009 Dr. Dahlen was CEO of the Danish biotech company Biolmage and previous to that president of lifesciences and senior vice president at PerkinElmer. Dr. Dahlen currently holds other board positions which include Proxeon, DxS Diagnostics, and has been a board member for DakoCytomation and Cantion.

Other news from the department people

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures
View topic world
Topic world Diagnostics

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures